Health AI Central
Share:
Peer-Reviewed Publication
Blood Adv2026June 30, 2026Journal Article

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Jacob D Soumerai1, Meghan C Thompson2, Ahmet Dogan3, Venkatraman E Seshan4, Kelsey Flaherty2, Natalie Slupe2, Jason Carter2, Ephraim Hochberg5, Jeffrey A Barnes5, Jeremy S Abramson6, Ariela Noy2, Colette N Owens7, M Lia Palomba2, Anita Kumar2, Lindsey Elizabeth Roeker4, Ronald W Takvorian4, Zachary D Epstein-Peterson3, Mark B Geyer2, Gilles A Salles2, Robert N Stuver2, Philip C Caron8, Prioty Islam2, Tamanna Haque2, Paola Ghione2, Raphael E Steiner2, Pallawi Torka9, Kevin A David4, Jennifer K Lue4, Paul A Hamlin3, Alison J Moskowitz2, Lorenzo Falchi2, Julie E Haydu10, Patrick Connor Johnson10, Joanna Mi10, Neena Mahajan2, Jessica Pendleton2, Alyssa Labarre2, Maria Chabowska2, Morgan Choma2, Clare Grieve2, Ashlee Joseph3, Colleen Dorsey2, Jamila Brutus2, Rosalba Martignetti6, Rachel Nazzaro1, Jayne Coyle1, Olivia Grace Maas1, De Zoysa Meemanage1, Elizabeth Simkins6, Akshata Kakolu1, Cameron Gordan1, Eshani Baez1, Bernadette Beatty1, Athina Apazidis1, Michelle Gulotta1, Sherry Ratcliff1, Jamie Hirata11, Mina Shahkarami12, Allison P Jacob13, Omar Abdel-Wahab2, Andrew D Zelenetz2
1Mass General Brigham Cancer Institute, Boston, Massachusetts, United States.
2Memorial Sloan Kettering Cancer Center, New York, New York, United States.
3Memorial Sloan-Kettering Cancer Center, New York, New York, United States.
4Memorial Sloan Kettering Cancer Center, United States.
5Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States.
6Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.
7Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States.
8Memorial Sloan Kettering Cancer Center, West Harrison, New York, United States.
9Memorial Sloan Kettering Cancer Center, Montvale, New Jersey, United States.
10Mass General Brigham Cancer Institute; Harvard Medical School, United States.
11BeOne Medicines, Ltd, San Carlos, California, United States.
12Genentech Inc., South San Francisco, California, United States.
13Adaptive Biotechnologies, Seattle, Washington, United States.
PubMed DOI

Abstract

Triplet regimens induce high rates of undetectable MRD at ≤10-4 (uMRD4) and appear to prolong progression-free survival (PFS) in treatment-naïve (TN) CLL, but the optimal treatment duration to minimize the risk of neutropenia/infections is unknown. In this phase 2 trial, we evaluated zanubrutinib, obinutuzumab, and venetoclax (BOVen) in TN CLL (NCT03824483). Our MRD-driven treatment/retreatment st…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.